Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: Ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 277-282

  Cunningham, D ^a   Dicato, M ^b   Verweij, J ^c   Crombez, R ^d   De Mulder, P ^e   Du Bois, A ^f   Stewart, A ^g   Smyth, J ^h   Selby, P ⁱ   Van Straelen, D ^j   Parideans, R ^k   McQuade, B ^l   McRae, J ^l  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d AZ Sint Lucas Brugge   (Belgium)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF FREIBURG   (Germany)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j VIRGA JESSE HOSPITAL   (Belgium)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

Cisplatin; Emesis; Nausea; Ondansetron; Repeated treatments

Indexed keywords

CISPLATIN; DEXAMETHASONE; LORAZEPAM; METOCLOPRAMIDE; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VERTIGO; VOMITING;

EID: 9244258535     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010572     Document Type: Article

References (15)

1. Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-84.
2. Lindley CM, Hirsch JD, O'Neill CV et al. Incidence and duration of chemotherapy induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989; 7, 8: 1142-9.
3. De Mulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in the prophylaxis of acute and delayed cisplatin induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40.
4. Coates A, Abraham S, Kaye SB et al. On the receiving end - patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-8.
5. 3, (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. New Engl J Med 1990; 322: 816-82.
6. Hainsworth J, Harvey W, Prendergrass K et al. A single-blinded comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991; 9: 721-8.
7. Roila F, Tonato M, Cognetti F et al. Prevention of cisplatin-induced emesis: A double-blind multicentre randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-8.
8. Grunberg SM, Akerley WL, Krailo MD et al. Comparison of metoclopramide and metoclopramide plus dexamethasone plus lorazepam for complete protection from cisplatinum-induced emesis. Cancer Invest 1986; 4: 379-85.
9. Smyth JF Coleman RE, Nicolson M et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br J Med 1991; 303: 1423-6.
10. Gralla R. The Management of chemotherapy induced nausea and vomiting. Med Clin N Am 1987; 71: 289-301.
11. Italian Group for Antiemetic Research. Differences in persistence of efficacy of two anti-emetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993; 11: 2396-404.
12. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983; 25 (Suppl 1): 1-7.
13. Roila F, Tonato M, Basurto C et al. Anti-emetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: A randomised double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989; 7: 1693-700.
14. Kris MG, Gralla RJ, Clark RA et al. Anti-emetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 1987; 60: 2816-22.
15. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncol 1992; 49: 295-304.